Stock Scorecard



Stock Summary for MoonLake Immunotherapeutics - Class A (MLTX) - $51.88 as of 12/20/2024 3:49:04 PM EST

Total Score

11 out of 30

Safety Score

41 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for MLTX

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for MLTX

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for MLTX

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for MLTX

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for MLTX (41 out of 100)

Stock Price Rating (Max of 10) 9
Historical Stock Price Rating (Max of 10) 5
Stock Price Trend (Max of 10) 10
Book Value (Max of 10) 4
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 4
Price to Earnings (Max of 10) 0

Latest News for for MLTX

MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11 9/9/2024 11:00:00 AM
Autoinjectors Market Size to Hit USD 3.8 Billion Milestone by 2034 with 16.2% CAGR Growth | Exclusive Report by Transparency Market Research, Inc. 8/19/2024 11:25:00 AM
MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis - MoonLake ( NASDAQ:MLTX ) 6/10/2024 12:00:00 PM
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update 5/7/2024 12:00:00 PM
MoonLake Jumps As It Looks To Take On AbbVie Blockbuster, Humira 3/11/2024 2:41:00 PM
Why Is MoonLake Immunotherapeutics Stock Trading Higher Today? - MoonLake ( NASDAQ:MLTX ) 3/11/2024 1:56:00 PM
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis ( PsA ) and other important updates at its R&D Day 3/10/2024 5:00:00 PM
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis ( PsA ) and other important updates at its R&D Day 3/10/2024 4:00:00 PM
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024 3/4/2024 1:00:00 PM
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday - NetApp ( NASDAQ:NTAP ) , Cooper Companies ( NASDAQ:COO ) , Dell Technologies ( NYSE:DELL ) 3/1/2024 4:18:00 PM

Financial Details for MLTX

Company Overview

Ticker MLTX
Company Name MoonLake Immunotherapeutics - Class A
Country USA
Description N/A
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 9/30/2024
Next Earnings Date 2/26/2025

Stock Price History

Last Day Price 51.88
Price 4 Years Ago 11.37
Last Day Price Updated 12/20/2024 3:49:04 PM EST
Last Day Volume 192,786
Average Daily Volume 201,083
52-Week High 64.98
52-Week Low 37.55
Last Price to 52 Week Low 38.16%

Valuation Measures

Trailing PE N/A
Industry PE 21.25
Sector PE 40.44
5-Year Average PE -259.95
Free Cash Flow Ratio 6.63
Industry Free Cash Flow Ratio 11.59
Sector Free Cash Flow Ratio 27.17
Current Ratio Most Recent Quarter 25.51
Total Cash Per Share 7.83
Book Value Per Share Most Recent Quarter 7.74
Price to Book Ratio 6.74
Industry Price to Book Ratio 5.00
Sector Price to Book Ratio 20.63
Price to Sales Ratio Twelve Trailing Months 0.00
Industry Price to Sales Ratio Twelve Trailing Months 81.68
Sector Price to Sales Ratio Twelve Trailing Months 24.53
Analyst Buy Ratings 11
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 63,064,000
Market Capitalization 3,271,760,320
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 27.95%
Reported EPS 12 Trailing Months -1.27
Reported EPS Past Year -1.17
Reported EPS Prior Year -0.76
Net Income Twelve Trailing Months -80,768,081
Net Income Past Year -36,007,260
Net Income Prior Year -49,973,249
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months 0.00

Balance Sheet

Total Cash Most Recent Quarter 493,924,691
Total Cash Past Year 511,008,237
Total Cash Prior Year 72,114,735
Net Cash Position Most Recent Quarter 493,924,691
Net Cash Position Past Year 511,008,237
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 495,675,683
Total Stockholder Equity Prior Year 48,898,296
Total Stockholder Equity Most Recent Quarter 488,195,325

Free Cash Flow

Free Cash Flow Twelve Trailing Months -81,086,502
Free Cash Flow Per Share Twelve Trailing Months -1.29
Free Cash Flow Past Year -43,062,801
Free Cash Flow Prior Year -55,909,909

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.71
MACD Signal 0.86
20-Day Bollinger Lower Band 43.86
20-Day Bollinger Middle Band 50.16
20-Day Bollinger Upper Band 56.45
Beta 1.28
RSI 49.49
50-Day SMA 48.45
150-Day SMA 31.97
200-Day SMA 26.50

System

Modified 12/21/2024 6:23:01 AM EST